Details for New Drug Application (NDA): 071311
✉ Email this page to a colleague
NDA 071311 describes NARCAN, which is a drug marketed by Adapt, Bristol Myers Squibb, and Emergent, and is included in five NDAs. It is available from six suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the NARCAN profile page.
The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
Summary for 071311
| Tradename: | NARCAN |
| Applicant: | Bristol Myers Squibb |
| Ingredient: | naloxone hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 071311
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1MG/ML | ||||
| Approval Date: | Jul 28, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
